A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
Valle, Juan W Armstrong, Anne C Newman, C Alakhov, V Pietrzynski, G Brewer, Julie Campbell, S Corrie, P Rowinsky, E K Ranson, Malcolm R
Valle, Juan W
Armstrong, Anne C
Newman, C
Alakhov, V
Pietrzynski, G
Brewer, Julie
Campbell, S
Corrie, P
Rowinsky, E K
Ranson, Malcolm R
Citations
Altmetric:
Abstract
To evaluate the antitumor activity of SP1049C, a novel P-glycoprotein targeting micellar formulation of doxorubicin, consisting of doxorubicin and two non-ionic block copolymers (pluronics), in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction (GEJ). Patients and
Description
Date
2011-10
Publisher
Collections
Keywords
Type
Article
Citation
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. 2011, 29 (5):1029-37 Invest New Drugs